Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Biliary Tract Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 250 articles: HTML format

Single Articles

December 2024
1. ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al
   Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
   Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
   PubMed     Abstract available
   
   
   
2. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
   Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
   Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
   PubMed     Abstract available
   
   
   November 2024
3. KARLSEN TH, Kaasen Jorgensen K, Bergquist A
   Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
   Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172.
   PubMed     Abstract available
   
   
   October 2024
4. FAN G, Tao C, Li L, Xie T, et al
   The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
   Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
   PubMed     Abstract available
   
   
   
5. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
   Role of microbiome in autoimmune liver diseases.
   Hepatology. 2024;80:965-987.
   PubMed     Abstract available
   
   
   September 2024
6. JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al
   Central role for cholangiocyte pathobiology in cholestatic liver diseases.
   Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093.
   PubMed     Abstract available
   
   
   
7. CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al
   Immunobiology of primary sclerosing cholangitis.
   Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080.
   PubMed     Abstract available
   
   
   August 2024
8. PANT K, Richard S, Peixoto E, Baral S, et al
   Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.
   Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055.
   PubMed     Abstract available
   
   
   
9. XIAO MH, Ma D, Wu S, Huang Z, et al
   Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
   Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064.
   PubMed     Abstract available
   
   
   
10. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    PubMed     Abstract available
    
    
    
11. BANALES JM, Lapitz A, Fabris L
    Comparative performance of methylation DNA markers, brushing cytology, and FISH in diagnosing malignant biliary strictures.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050.
    PubMed    
    
    
    July 2024
12. ZHANG X, Liu H, Cai P, Huang Z, et al
    Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031.
    PubMed     Abstract available
    
    
    
13. SUTTON H, Sokol RJ, Kamath BM
    IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?
    Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032.
    PubMed    
    
    
    
14. ZHUANG Y, Ortega-Ribera M, Szabo G
    Reply to: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017.
    PubMed    
    
    
    
15. YI C, Chen L, Tao B, Wang X, et al
    Letter to the Editor: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013.
    PubMed    
    
    
    
16. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    PubMed     Abstract available
    
    
    June 2024
17. ZHU M, Qu M, Lv S, Pan F, et al
    Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
    Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932.
    PubMed    
    
    
    
18. COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al
    Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970.
    PubMed     Abstract available
    
    
    
19. OH DY, Ikeda M, Lee CK, Rojas C, et al
    Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
    Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965.
    PubMed     Abstract available
    
    
    
20. YANG S, Fu J, Qin W, Wang R, et al
    Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases.
    Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957.
    PubMed     Abstract available
    
    
    
21. HUANG YH, Loftfield E, Argirion I, Adami HO, et al
    Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
    Hepatology. 2024;79:1324-1336.
    PubMed     Abstract available
    
    
    
22. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    PubMed     Abstract available
    
    
    May 2024
23. AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al
    An integrated analysis of bile acid metabolism in humans with severe obesity.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938.
    PubMed     Abstract available
    
    
    
24. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
    Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
    PubMed     Abstract available
    
    
    April 2024
25. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
    A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
    PubMed     Abstract available
    
    
    March 2024
26. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    PubMed     Abstract available
    
    
    
27. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    PubMed     Abstract available
    
    
    
28. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    PubMed     Abstract available
    
    
    
29. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
    Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
    PubMed     Abstract available
    
    
    
30. ZHUANG Y, Szabo G
    Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
    PubMed    
    
    
    
31. KELLERER M, Javed S, Casar C, Will N, et al
    Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
    PubMed     Abstract available
    
    
    
32. JIANG L, Yang Z
    Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
    PubMed    
    
    
    
33. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
    PubMed     Abstract available
    
    
    February 2024
34. ZHANG H, Zhu K, Zhang R, Guo Y, et al
    Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
    PubMed     Abstract available
    
    
    January 2024
35. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    PubMed     Abstract available
    
    
    
36. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    PubMed    
    
    
    
37. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    PubMed     Abstract available
    
    
    December 2023
38. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    PubMed    
    
    
    
39. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    PubMed    
    
    
    
40. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    PubMed     Abstract available
    
    
    November 2023
41. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    PubMed     Abstract available
    
    
    
42. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    PubMed     Abstract available
    
    
    
43. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    PubMed    
    
    
    
44. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    PubMed    
    
    
    
45. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    PubMed    
    
    
    
46. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    PubMed     Abstract available
    
    
    
47. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    PubMed     Abstract available
    
    
    October 2023
48. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    PubMed    
    
    
    
49. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    PubMed     Abstract available
    
    
    
50. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    PubMed    
    
    
    
51. 
    Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    PubMed    
    
    
    September 2023
52. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    PubMed     Abstract available
    
    
    
53. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    PubMed     Abstract available
    
    
    
54. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    PubMed     Abstract available
    
    
    August 2023
55. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    PubMed    
    
    
    
56. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    PubMed     Abstract available
    
    
    
57. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    PubMed     Abstract available
    
    
    
58. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    PubMed    
    
    
    July 2023
59. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    PubMed     Abstract available
    
    
    
60. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    PubMed     Abstract available
    
    
    
61. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    PubMed     Abstract available
    
    
    
62. 
    Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    PubMed    
    
    
    
63. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    PubMed    
    
    
    
64. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    PubMed    
    
    
    June 2023
65. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    PubMed     Abstract available
    
    
    
66. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    PubMed    
    
    
    May 2023
67. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    PubMed     Abstract available
    
    
    
68. 
    Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    PubMed    
    
    
    
69. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    PubMed     Abstract available
    
    
    
70. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    PubMed     Abstract available
    
    
    
71. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    PubMed    
    
    
    April 2023
72. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
    PubMed    
    
    
    
73. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    PubMed     Abstract available
    
    
    
74. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    PubMed     Abstract available
    
    
    
75. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    PubMed    
    
    
    
76. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    PubMed    
    
    
    
77. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    PubMed     Abstract available
    
    
    
78. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    PubMed     Abstract available
    
    
    
79. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    PubMed     Abstract available
    
    
    
80. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    PubMed    
    
    
    March 2023
81. HARTMANN P, Schnabl B
    Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
    Hepatology. 2023;77:709-711.
    PubMed    
    
    
    February 2023
82. MAMMADOV RA, Visseren T, Roest HP, van der Laan LJW, et al
    Letter to Editor: the mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. is the dysbiosis index really predictive for the recurrence of psc?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000338.
    PubMed    
    
    
    
83. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    PubMed     Abstract available
    
    
    
84. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000340.
    PubMed    
    
    
    
85. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    PubMed     Abstract available
    
    
    
86. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    PubMed     Abstract available
    
    
    
87. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    PubMed     Abstract available
    
    
    
88. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    PubMed     Abstract available
    
    
    
89. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    PubMed     Abstract available
    
    
    
90. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    PubMed    
    
    
    January 2023
91. ALI AH, Buness CW, Fischer R, Holtmann GJ, et al
    Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000304.
    PubMed    
    
    
    
92. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    Reply: insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 26. doi: 10.1097/HEP.0000000000000305.
    PubMed    
    
    
    
93. LAMARCA A, Edeline J
    Adjuvant treatment for biliary tract tumours: lost in a maze?
    Hepatology. 2023 Jan 23. doi: 10.1097/HEP.0000000000000301.
    PubMed    
    
    
    
94. LI Y, Yang B, Miao H, Liu L, et al
    Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000028.
    PubMed     Abstract available
    
    
    
95. UNALP-ARIDA A, Ruhl CE
    Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the United States.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000264.
    PubMed     Abstract available
    
    
    
96. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available
    
    
    
97. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    PubMed     Abstract available
    
    
    
98. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    PubMed     Abstract available
    
    
    
99. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    PubMed     Abstract available
    
    
    
100. HELLEN DJ, Bennett A, Malla S, Klindt C, et al
     Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000029.
     PubMed     Abstract available
     
     
     
101. NYHOLM I, Hukkinen M, Pihlajoki M, Davidson JR, et al
     Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000048.
     PubMed     Abstract available
     
     
     
102. MA J, Yang Z, Huang Z, Li L, et al
     Rngtt governs biliary-derived liver regeneration initiation by transcriptional regulation of mTORC1 and Dnmt1 in zebrafish.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000186.
     PubMed     Abstract available
     
     
     
103. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
     Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
     PubMed     Abstract available
     
     
     
104. HEINEMANN M, Adam R, Karam V, Schramm C, et al
     Letter to the Editor: Living donor liver transplantation for people with PSC.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
     PubMed    
     
     
     September 2022
105. BORAD MJ, Bai LY, Richards D, Mody K, et al
     Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study.
     Hepatology. 2022 Sep 24. doi: 10.1002/hep.32804.
     PubMed     Abstract available
     
     
     
106. HARPAVAT S, Hawthorne K, Setchell KDR, Narvaez Rivas M, et al
     Serum Bile Acids as a New Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy.
     Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800.
     PubMed     Abstract available
     
     
     
107. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
     Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
     Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
     PubMed     Abstract available
     
     
     
108. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
     AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.
     Hepatology. 2022 Sep 9. doi: 10.1002/hep.32771.
     PubMed    
     
     
     
109. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
     Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
     Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
     PubMed     Abstract available
     
     
     
110. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
     A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
     Hepatology. 2022 Sep 3. doi: 10.1002/hep.32773.
     PubMed     Abstract available
     
     
     August 2022
111. MAYO MJ
     Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
     Hepatology. 2022;76:518-531.
     PubMed     Abstract available
     
     
     
112. ZHANG X, Wang Z, Tang W, Wang X, et al
     Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
     Hepatology. 2022;76:317-329.
     PubMed     Abstract available
     
     
     July 2022
113. HEUCKE N, Keitel V
     COVID-19-associated cholangiopathy: What's left after the virus has gone?
     Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.
     PubMed    
     
     
     
114. HARTL L, Reiberger T, Trauner M
     On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
     Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.
     PubMed    
     
     
     June 2022
115. DENG M, Ran P, Chen L, Wang Y, et al
     Proteogenomic Characterization of Cholangiocarcinoma.
     Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
     PubMed     Abstract available
     
     
     
116. 
     Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
     Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
     PubMed     Abstract available
     
     
     
117. XU J, Wang Y, Khoshdeli M, Peach M, et al
     IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
     Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
     PubMed     Abstract available
     
     
     May 2022
118. HARTL L, Haslinger K, Angerer M, Semmler G, et al
     Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
     Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
     PubMed     Abstract available
     
     
     
119. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
     Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
     Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
     PubMed     Abstract available
     
     
     
120. ANDERSEN JB
     Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
     Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
     PubMed    
     
     
     
121. ZHOU J, Sun Y, Zhang W, Yuan J, et al
     Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
     Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
     PubMed     Abstract available
     
     
     April 2022
122. JIANG ST, Zhang L, Xu YY, Lu X, et al
     Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
     Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.
     PubMed    
     
     
     
123. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
     Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
     Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.
     PubMed    
     
     
     
124. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
     Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
     Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
     PubMed     Abstract available
     
     
     
125. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
     C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
     PubMed     Abstract available
     
     
     
126. MANDATO C, Vajro P
     Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
     Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
     PubMed    
     
     
     March 2022
127. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
     Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
     Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
     PubMed     Abstract available
     
     
     
128. JAVITT NB
     Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
     Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
     PubMed    
     
     
     
129. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
     The de-micellization hypothesis of water influx into bile ducts.
     Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.
     PubMed    
     
     
     
130. WANG T, Xu C, Zhang Z, Wu H, et al
     Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
     Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
     PubMed     Abstract available
     
     
     
131. BASS LM, Ye W, Hawthorne K, Leung DH, et al
     The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
     Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
     PubMed     Abstract available
     
     
     
132. 
     Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
     Hepatology. 2022;75:773.
     PubMed    
     
     
     
133. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
     Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
     PubMed     Abstract available
     
     
     February 2022
134. WU MJ, Shi L, Merritt J, Zhu AX, et al
     Biology of IDH Mutant Cholangiocarcinoma.
     Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
     PubMed     Abstract available
     
     
     
135. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
     Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
     Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
     PubMed     Abstract available
     
     
     
136. CHAUDHRY HUR, Hayat A, Ahmad A
     Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
     Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.
     PubMed    
     
     
     
137. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
     Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
     Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
     PubMed     Abstract available
     
     
     
138. LUO C, Xin H, Zhou Z, Hu Z, et al
     Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
     PubMed     Abstract available
     
     
     
139. YANG Y, Choi J, Chen Y, Invernizzi P, et al
     E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
     Hepatology. 2022;75:266-279.
     PubMed     Abstract available
     
     
     January 2022
140. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
     Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
     Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
     PubMed     Abstract available
     
     
     
141. ANDERSSON ER
     Outside influence: the extrahepatic duct as a source for bile duct regeneration.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
     PubMed    
     
     
     
142. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
     Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
     PubMed     Abstract available
     
     
     
143. 
     Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.
     PubMed    
     
     
     December 2021
144. PASTOR CM
     Reply to the review <>.
     Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.
     PubMed    
     
     
     
145. VARTAK N, Hengstler JG
     REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
     Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.
     PubMed    
     
     
     
146. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
     Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
     Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
     PubMed     Abstract available
     
     
     
147. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
     Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
     Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
     PubMed     Abstract available
     
     
     
148. SAPISOCHIN G, Ivanics T, Heimbach J
     Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
     PubMed     Abstract available
     
     
     November 2021
149. RUBINO JG, Flemming JA
     Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
     Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
     PubMed     Abstract available
     
     
     
150. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
     Menopausal hormone therapy and risk of biliary tract cancers.
     Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
     PubMed     Abstract available
     
     
     
151. LI H, Lan T, Liu H, Liu C, et al
     IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
     PubMed     Abstract available
     
     
     
152. WU N, Carpino G, Ceci L, Baiocchi L, et al
     MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
     PubMed     Abstract available
     
     
     
153. LEE BT, Tana MM, Kahn JA, Dara L, et al
     We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
     Hepatology. 2021;74:2876-2887.
     PubMed     Abstract available
     
     
     October 2021
154. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
     MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
     PubMed     Abstract available
     
     
     
155. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
     Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
     PubMed     Abstract available
     
     
     
156. LINDOR KD, Dawson PA, Trauner M
     Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
     PubMed     Abstract available
     
     
     
157. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
     Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
     Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
     PubMed     Abstract available
     
     
     
158. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
     Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
     Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
     PubMed     Abstract available
     
     
     
159. CHEN L, Yang H, Li H, He C, et al
     Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
     Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
     PubMed     Abstract available
     
     
     
160. LLEO A, Hirschfield GM
     Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
     Hepatology. 2021;74:2307.
     PubMed    
     
     
     
161. MA Y, Su H, Yuksel M, Longhi MS, et al
     Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
     Hepatology. 2021;74:2032-2046.
     PubMed     Abstract available
     
     
     September 2021
162. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
     Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
     Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
     PubMed     Abstract available
     
     
     
163. HUNG HY, Wang CC, Wei JC
     Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
     Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
     PubMed     Abstract available
     
     
     
164. VARTAK N, Hengstler JG
     Response to 21-1766: Challenging the dogma of canalicular bile flow.
     Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
     PubMed     Abstract available
     
     
     
165. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
     Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
     PubMed     Abstract available
     
     
     
166. JAVITT NB, Boyer JL
     Letter to the Editor: On the Mechanisms of Biliary Flux.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
     PubMed     Abstract available
     
     
     
167. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
     Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
     PubMed     Abstract available
     
     
     
168. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
     The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
     PubMed     Abstract available
     
     
     
169. AN J, Kim D, Oh B, Oh YJ, et al
     Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
     Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
     PubMed     Abstract available
     
     
     
170. WANG SS, Tang XT, Lin M, Yuan J, et al
     Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
     Hepatology. 2021;74:1578-1594.
     PubMed     Abstract available
     
     
     
171. WANG Y, Hylemon PB, Zhou H
     Long Noncoding RNA H19: A Key Player in Liver Diseases.
     Hepatology. 2021;74:1652-1659.
     PubMed    
     
     
     August 2021
172. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
     Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
     Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
     PubMed     Abstract available
     
     
     
173. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
     Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
     Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
     PubMed     Abstract available
     
     
     
174. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
     Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
     Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
     PubMed     Abstract available
     
     
     
175. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
     Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
     PubMed     Abstract available
     
     
     
176. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
     Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
     PubMed     Abstract available
     
     
     
177. LIN Y, Cai Q, Chen Y, Shi T, et al
     CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
     PubMed     Abstract available
     
     
     
178. ZENG R, Sha W, Leung FW, Chen H, et al
     Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
     Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
     PubMed     Abstract available
     
     
     July 2021
179. PANT K, Peixoto E, Richard S, Biswas A, et al
     Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
     PubMed     Abstract available
     
     
     
180. CAI P, Mao X, Zhao J, Nie L, et al
     Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
     PubMed     Abstract available
     
     
     
181. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
     Addressing social adversity to improve outcomes for children after liver transplant.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
     PubMed     Abstract available
     
     
     
182. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
     NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
     Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
     PubMed     Abstract available
     
     
     
183. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
     ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
     Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
     PubMed     Abstract available
     
     
     
184. ZHANG JW, Yang X, Ding HR, Zhang L, et al
     Is aspirin a drug or just a marker for biliary cancer?
     Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
     PubMed     Abstract available
     
     
     
185. LEE MH, Huang YH, Koshiol J
     Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
     Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
     PubMed     Abstract available
     
     
     
186. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
     Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
     Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
     PubMed     Abstract available
     
     
     
187. WANG H, Song X, Liao H, Wang P, et al
     Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
     Hepatology. 2021;74:248-263.
     PubMed     Abstract available
     
     
     June 2021
188. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
     On the mechanisms of biliary flux.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
     PubMed     Abstract available
     
     
     
189. SHI S, Chen S, Verstegen MMA, Pan Q, et al
     Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
     PubMed     Abstract available
     
     
     
190. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
     Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
     PubMed     Abstract available
     
     
     
191. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
     The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
     PubMed     Abstract available
     
     
     
192. LEE YT, Wang JJ, Luu M, Noureddin M, et al
     Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
     Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
     PubMed     Abstract available
     
     
     
193. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
     Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
     Hepatology. 2021;73:2397-2410.
     PubMed     Abstract available
     
     
     May 2021
194. LEPORE A, Choy PM, Lee NC, Carella MA, et al
     Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
     Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
     PubMed     Abstract available
     
     
     
195. SUN LY, Hu JY, Liang L, Tong XM, et al
     Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
     Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
     PubMed     Abstract available
     
     
     
196. JOHN BV, Deng Y, Martin P, Levy C, et al
     Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
     Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
     PubMed     Abstract available
     
     
     
197. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
     Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
     Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
     PubMed     Abstract available
     
     
     
198. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
     Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
     PubMed     Abstract available
     
     
     
199. JANSSON H, Sparrelid E
     Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
     PubMed     Abstract available
     
     
     
200. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
     Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
     PubMed     Abstract available
     
     
     
201. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
     Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
     Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
     PubMed     Abstract available
     
     
     
202. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
     Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
     Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
     PubMed     Abstract available
     
     
     
203. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
     Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
     Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
     PubMed     Abstract available
     
     
     April 2021
204. YOON JG, Kim MH, Jang M, Kim H, et al
     Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
     Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
     PubMed     Abstract available
     
     
     
205. XU Y, Leng K, Yao Y, Kang P, et al
     A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
     Hepatology. 2021;73:1419-1435.
     PubMed     Abstract available
     
     
     
206. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
     Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
     Hepatology. 2021;73:1399-1418.
     PubMed     Abstract available
     
     
     March 2021
207. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
     A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
     Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
     PubMed     Abstract available
     
     
     
208. BOERNER T, Drill E, Pak LM, Nguyen B, et al
     Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
     PubMed     Abstract available
     
     
     
209. LUO X, Campbell NA, He L, O'Brien DR, et al
     SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
     Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
     PubMed     Abstract available
     
     
     
210. WADA Y, Shimada M, Yamamura K, Toshima T, et al
     A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
     PubMed     Abstract available
     
     
     
211. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
     Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
     PubMed     Abstract available
     
     
     
212. KENDRE G, Marhenke S, Lorz G, Becker D, et al
     The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
     Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
     PubMed     Abstract available
     
     
     
213. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
     Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
     Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
     PubMed     Abstract available
     
     
     
214. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
     Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
     Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
     PubMed     Abstract available
     
     
     February 2021
215. CHIU M, Garabon J, Chen L, Karp N, et al
     Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
     Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
     PubMed     Abstract available
     
     
     
216. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
     Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
     PubMed     Abstract available
     
     
     
217. SHIOTA J, Samuelson LC, Razumilava N
     Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
     PubMed     Abstract available
     
     
     
218. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
     Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
     PubMed     Abstract available
     
     
     
219. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
     6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
     Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
     PubMed     Abstract available
     
     
     
220. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
     HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
     PubMed     Abstract available
     
     
     
221. JAVITT NB
     Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
     PubMed     Abstract available
     
     
     
222. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
     Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
     PubMed     Abstract available
     
     
     
223. ZHANG XF, Lv Y, Pawlik TM
     Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
     Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
     PubMed     Abstract available
     
     
     
224. NASSER-GHODSI N, Mara K, Watt KD
     De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
     Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
     PubMed     Abstract available
     
     
     January 2021
225. ITOH A, Adams D, Huang W, Wu Y, et al
     Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
     Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
     PubMed     Abstract available
     
     
     
226. LI J, Ye X, He S
     Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
     Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
     PubMed     Abstract available
     
     
     
227. ASSIS DN, Levy C
     Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
     Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
     PubMed     Abstract available
     
     
     
228. FENG GS, Hanley KL, Liang Y, Lin X, et al
     Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
     Hepatology. 2021;73 Suppl 1:104-114.
     PubMed     Abstract available
     
     
     
229. RIZVI S, Wang J, El-Khoueiry AB
     Liver Cancer Immunity.
     Hepatology. 2021;73 Suppl 1:86-103.
     PubMed    
     
     
     
230. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
     Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
     Hepatology. 2021;73 Suppl 1:49-61.
     PubMed     Abstract available
     
     
     December 2020
231. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
     Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
     Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
     PubMed     Abstract available
     
     
     November 2020
232. KNOOIHUIZEN SAI, Aday A, Lee WM
     Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
     PubMed     Abstract available
     
     
     
233. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
     Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
     PubMed     Abstract available
     
     
     
234. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
     Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
     PubMed     Abstract available
     
     
     
235. SATO K, Zhang W, Safarikia S, Isidan A, et al
     Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
     PubMed     Abstract available
     
     
     
236. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
     Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
     PubMed     Abstract available
     
     
     
237. MEADOWS V, Francis H
     DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
     Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
     PubMed     Abstract available
     
     
     
238. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
     Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
     Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
     PubMed     Abstract available
     
     
     October 2020
239. XU Y, Zhu Y, Hu S, Xu Y, et al
     Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
     Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
     PubMed     Abstract available
     
     
     
240. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
     Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
     PubMed     Abstract available
     
     
     
241. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
     Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
     Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
     PubMed     Abstract available
     
     
     
242. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
     Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
     Hepatology. 2020;72:1310-1326.
     PubMed     Abstract available
     
     
     September 2020
243. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
     DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
     PubMed     Abstract available
     
     
     
244. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
     Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
     PubMed     Abstract available
     
     
     August 2020
245. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
     Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
     Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
     PubMed     Abstract available
     
     
     July 2020
246. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
     Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
     PubMed     Abstract available
     
     
     
247. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
     Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
     PubMed     Abstract available
     
     
     
248. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
     Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
     Hepatology. 2020;72:359-360.
     PubMed    
     
     
     April 2020
249. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
     Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
     Hepatology. 2020;71:1331-1349.
     PubMed     Abstract available
     
     
     March 2020
250. LU ZN, Luo Q, Zhao LN, Shi Y, et al
     The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
     Hepatology. 2020;71:929-942.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.